Clinical trials: Follicular Thyroid Carcinoma
Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
This phase II trial is studying how well romidepsin works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine.
- Conditions
- Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
- Trial name
- NCT00098813
- Testing
- romidepsin, laboratory biomarker analysis, positron emission tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Nodule, Follicular Neoplasm
Diagnostic Accuracy of Shear-Wave Elastography for the Preoperative Risk Stratification of Follicular Lesions of the Thyroid
As many as 70-85% subjects diagnosed with a follicular lesion on biopsy and undergoing surgery will have benign lesions verified by histopathology after surgery.
- Trial name
- NCT03106337
- Testing
- Shear-Wave Elastography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Massachusetts General Hospital
Thyroid Neoplasm
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
Background: Patients who have advanced thyroid cancer have a low long-term survival rate. These types of thyroid cancer do not respond well to conventional surgery or radiation, or to specific thyroid cancer treatments such as…
- Trial name
- NCT01182285
- Testing
- Valproic Acid, Liothyronine Sodium
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Iodine I 131 in Treating Patients With Thyroid Cancer
RATIONALE: Radioactive iodine kills thyroid cancer cells by giving off radiation. PURPOSE: This clinical trial is studying the side effects, best dose, and how well iodine I 131 works in treating patients with thyroid cancer.
- Trial name
- NCT00416949
- Testing
- Patient-specific dosimetry
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Papillary Carcinoma
Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
This phase II trial is studying how well selumetinib works in treating patients with papillary thyroid cancer that did not respond to radioactive iodine.
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Papillary Carcinoma, Stage III Thyroid Gland Papillary Carcinoma
- Trial name
- NCT00559949
- Testing
- Laboratory Biomarker Analysis, Selumetinib
- Where
- 6 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Neoplasms
Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
This was a parallel group, randomized, double blind, placebo controlled, multicentre study designed to assess whether vandetanib (ZD6474) conferred an improvement in PFS as compared to placebo in participants with locally…
- Trial name
- NCT00537095
- Testing
- Vandetanib
- Where
- 15 sites in Belgium, Denmark and 5 more
- Volunteers
- 164 people
- Sponsor
- Genzyme, a Sanofi Company
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis
Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
This phase II trial is studying how well aflibercept works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine therapy.
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma
- Trial name
- NCT00729157
- Testing
- Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
This phase II trial studies how well iodine I-131 works with or without selumetinib in treating patients with thyroid cancer that has returned (recurrent) or has spread from where it started to other places in the body…
- Conditions
- Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7
- Trial name
- NCT02393690
- Testing
- Iodine I-131, Selumetinib
- Where
- 11 sites in United States
- Volunteers
- 60 people
- Sponsor
- Academic and Community Cancer Research United
Insular Thyroid Cancer, Recurrent Thyroid Cancer
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
This phase II trial is studying how well bortezomib works in treating patients with metastatic thyroid cancer that did not respond to radioactive iodine therapy.
- Conditions
- Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer
- Trial name
- NCT00104871
- Testing
- Bortezomib
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment.
- Conditions
- Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Follicular Carcinoma, Stage I Thyroid Gland Papillary Carcinoma
- Trial name
- NCT01811212
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have locally advanced or…
- Trial name
- NCT00095836
- Testing
- Gefitinib
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery.
- Conditions
- Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma
- Trial name
- NCT02973997
- Testing
- Laboratory Biomarker Analysis, Lenvatinib, Lenvatinib Mesylate
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Academic and Community Cancer Research United
Thyroid Neoplasms
REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas
The primary objective of the study is to assess the anti-tumor activity of REVLIMID® (lenalidomide), administered as a single agent, in patients with distantly metastatic thyroid carcinomas which are unresponsive to systemic…
- Trial name
- NCT00287287
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Kenneth Ain
Thyroid Cancer
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
The purpose of this study is to find out what effects, good and/or bad, the combination of sorafenib and temsirolimus will have on thyroid cancer.
- Trial name
- NCT01025453
- Testing
- Temsirolimus and Sorafenib
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Insular Thyroid Cancer, Recurrent Thyroid Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with metastatic and/or locally advanced or locally recurrent thyroid cancer.
- Conditions
- Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer
- Trial name
- NCT00134043
- Testing
- vorinostat
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Neoplasms
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine
- Trial name
- NCT00984282
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 81 sites in United States, Austria and 16 more
- Volunteers
- 417 people
- Sponsor
- Bayer
Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
This phase II trial studies how well lenvatinib works when given together with standard of care iodine I-131 in treating patients with radioactive iodine-sensitive differentiated thyroid cancer.
- Conditions
- Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
- Trial name
- NCT03506048
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Emory University
Head and Neck Cancer
Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer
RATIONALE: Drugs such as valproic acid may make thyroid cancers more radioiodine sensitive, which will allow for detection of tumor and make further ablation treatment effective.
- Trial name
- NCT00525135
- Testing
- Valproic Acid
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Francisco
Thyroid Cancer, Thyroid Cancer, Medullary
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
Participants will have been diagnosed with advanced progressive thyroid cancer and are about to start treatment with a tyrosine kinase inhibitor (TKI).
- Conditions
- Thyroid Cancer, Thyroid Cancer, Medullary, Differentiated Thyroid Cancer, Papillary Thyroid Cancer
- Trial name
- NCT03630120
- Testing
- Lenvatinib, Sorafenib, Cabozantinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute